iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer

• Published in: Cell reports. Medicine 2023-12, Vol.4 (12), p.101327-101327, Article 101327
• Main Authors: Furukawa, Yoshiki, Ishii, Midori, Ando, Jun, Ikeda, Kazuya, Igarashi, Kyomi J, Kinoshita, Shintaro, Azusawa, Yoko, Toyota, Tokuko, Honda, Tadahiro, Nakanishi, Mahito, Ohshima, Koichi, Masuda, Ayako, Yoshida, Emiko, Kitade, Mari, Porteus, Matthew, Terao, Yasuhisa, Nakauchi, Hiromitsu, Ando, Miki
• Format: Article
• Language: English
• ISSN: 2666-3791; 2666-3791
• DOI: 10.1016/j.xcrm.2023.101327

Functionally rejuvenated human papilloma virus-specific cytotoxic T lymphocytes (HPV-rejTs) generated from induced pluripotent stem cells robustly suppress cervical cancer. However, autologous rejT generation is time consuming, leading to difficulty in treating patients with advanced cancer. Although use of allogeneic HPV-rejTs can obviate this, the major obstacle is rejection by the patient immune system. To overcome this, we develop HLA-A24&-E dual integrated HPV-rejTs after erasing HLA class I antigens. These rejTs effectively suppress recipient immune rejection while maintaining more robust cytotoxicity than original cytotoxic T lymphocytes. Single-cell RNA sequencing performed to gain deeper insights reveal that HPV-rejTs are highly enriched with tissue resident memory T cells, which enhance cytotoxicity against cervical cancer through TGFβR signaling, with increased CD103 expression. Genes associated with the immunological synapse also are upregulated, suggesting that these features promote stronger activation of T cell receptor (TCR) and increased TCR-mediated target cell death. We believe that our work will contribute to feasible "off-the-shelf" T cell therapy with robust anti-cervical cancer effects.